A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors

被引：7
|
作者：
Rodon, Jordi
Goyal, Lipika
Mercade, Teresa Macarulla
Ikeda, Masafumi
Kondo, Shunsuke
Oh, Do-Youn
Bai, Li-Yuan
Ueno, Makoto
Italiano, Antoine
Papadopoulos, Kyriakos
Spigel, David
Kizilbash, Sani H.
Cosman, Rasha
Park, Joon Oh
Chen, Li-Tzong
Yokota, Tomoya
Turk, Anita A.
Liao, Chih-Yi
Shroff, Rachna
El-Khoueiry, Anthony
Satoh, Taroh
Hollebecque, Antoine
Borad, Mitesh J.
Azad, Nilofer
Jaeckle, Kurt A.
Loong, Herbert H.
Adeva, Jorge
Yong, Wei Peng
Zhao, Junjie
Liu, Hui
Szpurka, Anna M.
Gueorguieva, Ivelina
Pradhan, Kamnesh R.
Xu, Xiaojian
Harding, James J.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT098
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
    Harding, J.
    Ikeda, M.
    Goyal, L.
    Rodon, J.
    Bai, L.
    Oh, D.
    Park, J.
    Chen, L.
    Ueno, M.
    Liao, C.
    Kondo, S.
    Cosman, R.
    Yokota, T.
    Shroff, R.
    Satoh, T.
    Palmieri, L.
    Hollebecque, A.
    Adeva, J.
    Bender, M.
    Liu, H.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S161 - S161
  • [2] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies
    DiNardo, Courtney D.
    Montesinos, Pau
    Benajiba, Lina
    Triguero, Ana
    Recher, Christian
    Schuh, Andre C.
    Heiblig, Mael
    Bajel, Ashish
    Pigneux, Arnaud
    Alonso-Domiguez, Juan M.
    Fathi, Amir T.
    Grove, Carolyn
    Hou, Hsin-An
    Heuser, Michael
    Assouline, Sarit
    Fleming, Shaun
    Shin, Dong-Yeop
    Sweet, Kendra
    Odenike, Olatoyosi
    Altman, Jessica
    Ooi, Melissa Gaik Ming
    Lao Zhentang
    Vey, Nobert
    Zeidner, Joshua
    Salhotra, Amandeep
    Wang, Eunice
    Schiller, Gary
    Porkka, Kimmo
    Zuckerman, Tsila
    Havelange, Violaine
    Jonas, Brian A.
    Narayanan, Sujaatha
    Jang, Jun Ho
    Lee, Je-Hwan
    Szpurka, Anna M.
    Heirich, Dana
    Chen, Hsiao Rong
    Hanft, Violet
    Zhao, Junjie
    Gueorguieva, Ivelina
    Zhang, Yin
    Stein, Eytan M.
    CANCER RESEARCH, 2023, 83 (08)
  • [3] A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.
    Pauff, James Michael
    Papadopoulos, Kyriakos P.
    Janku, Filip
    Turk, Anita Ahmed
    Goyal, Lipika
    Shroff, Rachna T.
    Shimizu, Toshio
    Ikeda, Masafumi
    Azad, Nilofer Saba
    Cleary, James M.
    Peters, Mary Linton Bounetheau
    Borad, Mitesh J.
    Jaeckle, Kurt A.
    Kizilbash, Sani Haider
    Tupper, Rebecca
    Furin, Carrie E.
    Hanley, Matthew P.
    Hill, Elizabeth Goodwin
    Xu Xiaojian
    Harding, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [4] A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)
    Stein, Eytan M.
    Konopleva, Marina
    Gilmour, Raymond
    Szpurka, Anna M.
    Hill, Elizabeth
    Ward, Renee
    Kantarjian, Hagop M.
    Dinardo, Courtney D.
    BLOOD, 2020, 136
  • [5] Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma
    Mellinghoff, Ingo K.
    Penas-Prado, Marta
    Peters, Katherine B.
    Cloughesy, Timothy Francis
    Burris, Howard A.
    Maher, Elizabeth A.
    Janku, Filip
    Cote, Gregory Michael
    De La Fuente, Macarena Ines
    Clarke, Jennifer
    Steelman, Lori
    Le, Kha
    Zhang, Yanwei
    Sonderfan, Alison
    Hummel, Diana
    Schoenfeld, Steven
    Yen, Katharine
    Pandya, Shuchi Sumant
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Identification and characterization of LY3410738, a novel covalent inhibitor of cancer-associated mutant Isocitrate Dehydrogenase 1 (IDH1)
    Brooks, Nathan
    DeWalt, Robin
    Boulet, Serge
    Lu, ZhaoHai
    Kays, Lisa
    Cavitt, Rachel
    Gomez, Sandra
    Strelow, John
    Milligan, Paul
    Roth, Kenneth
    Bauer, Renato
    Antonysamy, Stephen
    Hahn, Patric
    Rankovic, Zoran
    McCann, Denis
    Mo, Gary
    Tiu, Ramon
    Burkholder, Timothy
    Geeganage, Sandaruwan
    Gilmour, Raymond
    CANCER RESEARCH, 2019, 79 (13)
  • [7] The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
    Natsume, Atsushi
    Arakawa, Yoshiki
    Narita, Yoshitaka
    Sugiyama, Kazuhiko
    Hata, Nobuhiro
    Muragaki, Yoshihiro
    Shinojima, Naoki
    Kumabe, Toshihiro
    Saito, Ryuta
    Motomura, Kazuya
    Mineharu, Yohei
    Miyakita, Yasuji
    Yamasaki, Fumiyuki
    Matsushita, Yuko
    Ichimura, Koichi
    Ito, Kazumi
    Tachibana, Masaya
    Kakurai, Yasuyuki
    Okamoto, Naoko
    Asahi, Takashi
    Nishijima, Soichiro
    Yamaguchi, Tomoyuki
    Tsubouchi, Hiroshi
    Nakamura, Hideo
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2023, 25 (02) : 326 - 336
  • [8] NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors
    Cecchini, Michael
    Pilat, Mary Jo
    Uboha, Nataliya
    Azad, Nilofer S.
    Cho, May
    Davis, Elizabeth J.
    Ahnert, Jordi Rodon
    Tinoco, Gabriel
    Shapiro, Geoff I.
    Khagi, Simon
    Powers, Benjamin
    Groisberg, Roman
    Drappatz, Jan
    Chen, Li
    Das, Biswajit
    Bao, Xun
    Li, Jing
    Patel, Abhijit
    Niger, Monica
    Doroshow, Deborah
    Durecki, Diane
    Boerner, Scott
    Bindra, Ranjit
    Ivy, Percy
    Shyr, Yu
    LoRusso, Patricia
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [9] Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
    Lowery, Maeve A.
    Burris, Howard A., III
    Janku, Filip
    Shroff, Rachna T.
    Cleary, James M.
    Azad, Nilofer S.
    Goyal, Lipika
    Maher, Elizabeth A.
    Gore, Lia
    Hollebecque, Antoine
    Beeram, Muralidhar
    Trent, Jonathan C.
    Jiang, Liewen
    Fan, Bin
    Aguado-Fraile, Elia
    Choe, Sung
    Bin Wu
    Gliser, Camelia
    Agresta, Samuel, V
    Pandya, Shuchi S.
    Zhu, Andrew X.
    Abou-Alfa, Ghassan K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (09): : 711 - 720
  • [10] LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)
    Salama, Vivian
    Brooks, Nathan
    Skwarska, Anna
    Kays, Lisa
    Milligan, Paul
    Newell, Katherine
    Roth, Kenneth
    Geeganage, Sandaruwan
    Gilmour, Raymond
    Chan, Steven M.
    Sarry, Jean-Emmanuel
    Sabatier, Mary
    DiNardo, Courtney
    Konopleva, Marina
    CANCER RESEARCH, 2020, 80 (16)
12345